Stephanie Cheung
Nephrology · Orange, CANPI 1417136219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Baxter Healthcare at 24.1% of the total. That places this record below the midpoint for nephrology clinicians in CA, where the typical reported total is $1,018.
Across 12 payments — averaging $58.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$168
- Vantive US Healthcare LLC$154
- Mallinckrodt Hospital Products Inc.$150
- Travere Therapeutics, Inc.$121
- Novartis$105
Across 4 payments — averaging $263,008 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.1M
What the payments were for
- Food & beverage$698100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 3 | $168 |
| Vantive US Healthcare LLC | 6 | $154 |
| Mallinckrodt Hospital Products Inc. | 1 | $150 |
| Travere Therapeutics, Inc. | 1 | $121 |
| Novartis | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$150
How this compares
$698 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 102 | $51,964 |
| VelphoroSucroferric Oxyhydroxide | 11 | $33,069 |
| Sevelamer Carbonate | 67 | $17,524 |
| Lanthanum Carbonate | 19 | $8,223 |
| Terazosin Hcl | 67 | $3,969 |
| Calcium Acetate | 30 | $3,723 |
| Losartan Potassium | 180 | $2,261 |
| Atorvastatin Calcium | 166 | $2,134 |
| Potassium Chloride | 50 | $2,049 |
| Humulin NInsulin Nph Human Isophane | 20 | $2,015 |
| Furosemide | 130 | $1,950 |
| Sodium Polystyrene Sulfonate | 30 | $1,909 |
| Amlodipine Besylate | 150 | $1,883 |
| Gentamicin Sulfate | 55 | $1,738 |
| Lisinopril | 140 | $1,687 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Orange
- Yasir QaziOrange$618K
- Ramy HannaOrange$446K
- Kamyar KalantarOrange$421K
- Rebecca AhdootOrange$66K
- Yongen ChangOrange$48K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.